Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001294406 | SCV001483284 | uncertain significance | Developmental and epileptic encephalopathy, 14; Autosomal dominant nocturnal frontal lobe epilepsy 5 | 2022-11-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 998535). This variant has not been reported in the literature in individuals affected with KCNT1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 540 of the KCNT1 protein (p.Gln540Arg). |
Ambry Genetics | RCV002543027 | SCV003549999 | uncertain significance | Inborn genetic diseases | 2021-01-26 | criteria provided, single submitter | clinical testing | The c.1619A>G (p.Q540R) alteration is located in exon 16 (coding exon 16) of the KCNT1 gene. This alteration results from a A to G substitution at nucleotide position 1619, causing the glutamine (Q) at amino acid position 540 to be replaced by an arginine (R). The p.Q540R alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |